Biogen Idec (NQ:BIIB)

219.88 -2.94 (-1.32%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

62 63 Next >

Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding ↗

March 06, 2025

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs and limited benefit. Stakeholders can submit feedback until March 27, 2025,...

Via Benzinga

Stocks Plummet As Trade Partners Retaliate Against Tariffs ↗

March 04, 2025

Stocks are free falling as President Donald Trump's tariffs against Mexico, Canada, and China take effect.

Via Talk Markets

Topics Government Stocks / Equities World Trade

3 Reasons BIIB is Risky and 1 Stock to Buy Instead

March 03, 2025

Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now trades at $140.49. This was partly driven by its softer quarterly results and...

Via StockStory

Synchronicity: Denying The Unexplainable ↗

February 24, 2025

Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?

Via Talk Markets

Topics Stocks / Equities

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects ↗

February 24, 2025

Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing...

Via Benzinga

Biogen Analysts Lower Their Forecasts After Q4 Results ↗

February 13, 2025

Via Benzinga

Forecasting The Future: 10 Analyst Projections For Biogen ↗

February 13, 2025

Via Benzinga

Biogen Stock Is Mutating Into a Value Play

February 20, 2025

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

Via MarketBeat

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal ↗

February 18, 2025

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

Via Benzinga

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

February 18, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For February 12, 2025 ↗

February 12, 2025

Via Benzinga

February 18, 2025

From Biogen Inc.

Via GlobeNewswire

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts ↗

February 13, 2025

Biogen's Q4 EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.

Via Benzinga

Top S&P500 movers in Wednesday's session ↗

February 12, 2025

Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook ↗

February 12, 2025

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Via Benzinga

These S&P500 stocks have an unusual volume in today's session ↗

February 12, 2025

Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.

Via Chartmill

These S&P500 stocks are moving in today's session ↗

February 12, 2025

Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

Biogen (BIIB) Q4 2024 Earnings Call Transcript ↗

February 12, 2025

BIIB earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday? ↗

February 12, 2025

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New...

Via Benzinga

Topics Economy

Wednesday's session: gap up and gap down stock in the S&P500 index ↗

February 12, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the S&P500 gap up and gap down stocks in today's session.

Via Chartmill

Biogen Stock Slides To Fresh 12-Year Lows As Profit Outlook Misses, But Retail Snaps Up The Dip ↗

February 12, 2025

The company's breakthrough Alzheimer's drug, Leqembi, generated $87 million in Q4 sales, well ahead of the $67 million analysts expected.

Via Stocktwits

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma ↗

February 12, 2025

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma.

Via Benzinga

Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates

February 12, 2025

Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 2.9% year on year to $2.45 billion. Its non-GAAP profit of $3.44 per share was 2.3%...

Via StockStory

Topics Artificial Intelligence

Why Investors Might Hammer Biogen Despite Its Earnings Beat ↗

February 12, 2025

Biogen beat Q4 views Wednesday, but guided lower on 2025 profit.

Via Investor's Business Daily

US Stocks Set For A Cautious Start Ahead Of Inflation Data: Expert Says 'Strong Bull Markets Tend To Roar Back To Life After Corrections' ↗

February 12, 2025

U.S. stock futures fell on Wednesday after a mixed close on Tuesday as Federal Reserve Chairman Jerome Powell Congress testimony.

Via Benzinga

Topics Economy

Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

February 12, 2025

Via Benzinga

What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday? ↗

February 11, 2025

Biogen faces revenue challenges as Leqembi sales lag projections. Investors watch its pipeline expansion and strategic moves amid upcoming Q4 earnings.

Via Benzinga

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect

February 11, 2025

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.

Via StockStory

Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok ↗

January 31, 2025

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok.

Via Benzinga

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

January 31, 2025

From Biogen Inc.

Via GlobeNewswire

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.